Beyond LDL cholesterol in assessing cardiovascular risk: Apo B or LDL-P?

Clinical Chemistry

Volumn 59, Issue 5, 2013, Pages 723-725

  Master, Stephen R ^a   Rader, Daniel J ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CARDIOVASCULAR RISK; DISEASE MARKER; EDITORIAL; GENETIC VARIABILITY; HUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN BLOOD LEVEL;

APOLIPOPROTEINS B; BLOOD CHEMICAL ANALYSIS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY;

EID: 84876903427     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2013.203208     Document Type: Editorial

References (15)

1. Strong A, Rader DJ. Clinical implications of lipid genetics for cardiovascular disease. Curr Cardiovasc Risk Rep 2010;4:461-8.
2. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81.
3. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 2002;43:1363-79.
4. Dati F, Tate J. Reference materials for the standardization of the apolipoproteins A-I and B, and lipoprotein(a). EJIFCC 2002;13(3):[7 p.].
5. Warnick GR, Kimberly MM, Waymack PP, Leary ET, Myers GL. (2008). Standardization of measurements for cholesterol, triglycerides, and major lipoproteins. Lab Med 2008;39:481-90.
6. Myers GL, Wilson PWF, Cooper GR, Grundy SM, Labarthe DR. Apolipoproteins A-I and B and cardiovascular disease risk. In: Myers GL, ed. Emerging biomarkers for primary prevention of cardiovascular disease and stroke. Washington (DC): AACC, National Academy of Clinical Biochemistry; 2009. p 35-41.
7. Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007;298:776-85. (Pubitemid 47263160)
8. Sniderman AD, Williams K, Contois JH, Moonroe HM, McQueen MJ, de Graaf J, Furberg CD. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 2011;4:337-45.
9. The Emerging Risk Factor Collaboration. Lipid-related markers and cardiovascular disease prediction. JAMA 2012;307:2499-506.
10. Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult: 2009 recommendations. Can J Cardiol 2009;25:567-79.
11. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 2006;26:847-70. (Pubitemid 44716510)
12. Cromwell WC, Barringer TA. Low-density lipoprotein and apolipoprotein B: clinical use in patients with coronary heart disease. Curr Cardiol Rep 2009;11:468-75.
13. Cole TG, Contois JH, Csako G, McConnell JP, Remaley AT, Devaraj S, et al. Association of apolipoprotein B and nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 clinical studies: assessment by the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices. Clin Chem 2013;59:752-70.
14. Mackey RH, Greenland P, Goff DC Jr, Lloyd-Jones D, Sibley CT, Mora S. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 2012;60:508-16.
15. deGoma EM, Rader DJ. High-density lipoprotein particle number: a better measure to quantify high-density lipoprotein? J Am Coll Cardiol 2012;60:517-20.